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Abstract
The primary etiology of nosocomial infections derives from the following
pathogenic ESKAPE organisms: Enterococcus faecium/faecalis, Staphyloccoccus
aureus,

Klebsiella

pneumoniae,

Acinetobacter

baumanni,

Pseudomonas

aeruginosa and Enterobacter species. These opportunistic organisms are multidrug
resistant and have the ability to form biofilm, which pose a great threat to clinical
medicine. Evidence has shown catechins found in green tea (Camellia sinensis),
have antibacterial activity. In this study, a modified polyphenolic catechin
compound Epigallocatechin-3-gallate stearate (EGCG-S) was used to research its
potential to inhibit ESKAPE growth and biofilm formation. In addition, synergistic
ability of EGCG-S with antibiotics was also studied. Disk diffusion and colony
forming unit assays were conducted to study the effects of EGCG-S, with and
without antibiotics on the ESKAPE bacteria. Growth in the presence of EGCG-S
was monitored and biofilm formation was analyzed. In all of the microorganisms,
EGCG-S was able to enhance the antimicrobial activity of some antibiotics,
converting them from resistant to sensitive or intermediate. The results indicated
that EGCG-S can inhibit the growth and biofilm formation of bacteria at both 250
and 500 µg/ml.
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Introduction
Bacterial Resistance
Microorganisms that previously did not pose a great threat to our global health are
now causing severe diseases in humans and wildlife, due to the rise of multi drug resistant
(MDR) organisms (Antibiotic 2017; Shin et al. 2018). The upsurge in MDR organisms is
attributed to bacteria, virus and fungi is ability to quickly adapt/acquire resistance to
medications (antifungals, antibiotics, and antivirals) (Antibiotic 2017; Shin et al. 2018).
These microorganisms possess the physiological advantage of genetic plasticity, due to
horizontal gene transfer, therefore, they can quickly adapt and evade present day
medications (Antibiotic 2017; Shin et al. 2018). Thus, they outsmart the host’s immune
system and use their hosts as a vector, which spreads MDR organisms communally (J.W
Betts et al., 2011).
The multifactorial causes of antibiotic resistance include inadequate diagnostic
techniques, superfluous use of antibiotics and the use of antiseptics (Antibiotic 2017; Shin
et al. 2018). In health care settings, harsh chemicals are used readily to clean surfaces
leaving behind antibiotic resistant pathogens that are easily spread through medical
equipment and medical personal (Saccucci et al. 2018). Therefore, nosocomial infections
have become more virulent and are easily transmitted to immunocompromised patients
with long hospital stays (Saccucci et al. 2018). These MDR organisms are opportunistic
and do not normally impact healthy individuals, unless it is a severely virulent strain
(Antolak et al. 2017; Saccucci et al. 2018)
Additionally, another mode of transmission of MDR bacteria is through
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consumption, grocery store products contain antibiotic resistant bacteria in various
products (Antolak et al. 2017). Cheese, meat, fruit, canned food and vegetables all contain
preservatives, which aim to inhibit microorganismal growth, however, some are ineffective
and cause consumers severe infections (Antolak et al. 2017).
Mechanisms of Bacterial Resistance
Bacteria attain antibiotic resistance intrinsically or through acquired resistance
(Alekshun & Levy, 2015). Intrinsic resistance is a species’ ability to evolve resistance
against antimicrobial agents that are naturally found in their habitat (Munita et al., 2016).
Efflux pumps are common intrinsic mechanisms that allow bacteria to eject and expel
antibiotics, which will be discussed further below (Alekshun & Levy, 2015).
Acquired resistance is categorized by species who were once susceptible to antibiotics and
are now resistant to those antibiotics (Munita et al., 2016). They are able to acquire
resistance through horizontal gene transfer in the three ways: transformation, transduction
and conjugation (Rogers et al., 2018).
Bacteria acquire antibiotic resistance genes via transformation from free DNA,
transduction from viral DNA and conjugation through a plasmid (Alekshun & Levy, 2015).
Transformation is when free DNA undergoes recombination, while an antibiotic resistance
gene is inserted into the organisms’ chromosome (Alekshun & Levy, 2015). Free DNA is
commonly in integron form, containing genetic elements in cassettes. Cassettes are
captured genes that can be carried, expressed and integrated into a chromosome via
recombination (Domingues et al. 2012). Another example of mobile DNA that can
transform a chromosome is a transposon (Alekshun & Levy, 2015). There are three
common types of transposons: 1. complex contains genetic material for various proteins in
11

addition to antibiotic resistance genes, 2. composite which contain genes that encode
transposition, and 3. Conjugative which is the ability to transfer resistance genes through
cell to cell interaction (Alekshun & Levy, 2015; Rogers et al., 2018). Transduction is the
process in which antibiotic resistance is acquired from foreign viral DNA (bacteriophage),
through transposition (Alekshun & Levy, 2015; Rogers et al., 2018). Transposition is an
alteration of gene order when a gene is inserted into the chromosome, commonly causing
a mutation (Alekshun & Levy, 2015). Conjugation is when a plasmid replicates
independently within an organism expressing resistance, although, plasmids can also
contain transposable elements that can integrate into the chromosome via transposition and
recombination (Alekshun & Levy, 2015).
There are four common antibiotic resistance mechanisms that are acquired; Efflux
pumps, blocked penetration, inactivation of enzymes and target modification shown in
Diagram 1 (Tu, 2010). Efflux pumps allow bacteria to regulate the amount of antibiotics
within the cell, decreasing the dose it is subjected to resulting in survival (Tu, 2010).
Blocked penetration is when an organism has the ability to accumulate the antibiotics, but
does not allow it to reach its cellular target (Tu, 2010). Bacteria can gain a resistance gene
that encodes for an enzyme that inactivates the antibiotic listed below (Tu, 2010). Target
modification resistance is when a bacteria is able to alter the antibiotic binding site
structurally and the antibiotic will not be able to bind (Tu, 2010).
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Figure 1: Mechanisms of bacterial resistance and the specific groups of antibiotics that
are inactivated through these mechanisms (Tu, 2010).
ESKAPE organisms
The ESKAPE group consists of the following bacterial species: Enterococcus faecium,
Staphyloccoccus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas
aeruginosa and Enterobacter spp.. The ESKAPE group organisms are the leading cause
of nosocomial infections. The ESKAPE organisms are on the World Health Organization
(WHO) priority pathogens for research development (R&D) of new antibiotics (De
Freitas, 2013; Santajit & Indrawattana, 2016). These multidrug resistant bacteria pose a
great threat to clinical medicine, due to their antibiotic resistant isolates, extremely
virulent genetic strains, decreased antibiotic cell permeability and their ability to form
biofilm (Santajit & Indrawattana, 2016).
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a.

Enterococcus faecium/faecalis
Enterococcus faecium and faecalis, mostly endogenous opportunistic
infections, are the only species out of 38 that make up the genera Enterococcus that
are clinically pertinent (Quiloan, Vu, & Carvalho, 2012; Santajit & Indrawattana,
2016). These gram positive facultative anaerobes are found in pairs and chains and
colonize the normal flora of the gastrointestinal tract in mammals (Quiloan et al.,
2012; Santajit & Indrawattana, 2016).
E. faecium is on the World Health Organization (WHO) priority pathogens
list for research and development (R&D) of new antibiotics and is listed as a high
priority pathogen (level 2) (De Freitas, 2013). E. faecium is highly resistant to
vancomycin and is thought to be transmitted through humans during consumption
of farm animals as they are a reservoir for Enterococcus faecalis and faecium
(Aarestrup et al., 2000). Resistance genes are found on their conjugative plasmids
and transposons (Aarestrup et al., 2000). These organisms can cause various
diseases including endocarditis, urinary tract infections, post-surgical infections
and during wound healing, septicemia, meningitis and pelvic/intraabdominal
infections (Quiloan et al., 2012).
Various studies have concentrated on comparing E. faecium and E. faecalis
antibiotic resistant strains (Aarestrup et al., 2000). A study published by the journal
of Diagnostic Microbiology and Infectious Disease found that both isolates from
human stool samples, pigs and chickens, specifically broilers (bred for
consumption), contained analogous patterns of resistance and genes encoding for
resistance; signifying resistance transmission among broilers, humans and pigs
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(Aarestrup et al., 2000). The researchers in the aforementioned study tested for
antibiotic resistance genes of twelve different antimicrobial agents utilizing
forward and reverse primers to test the isolates for potential susceptibility or
resistance (Aarestrup et al., 2000). The transmission of antibiotic resistant
E.faecalis and E.faecium between chickens, humans and pigs was determined to be
likely after utilizing the primers and analyzing the isolates from multiple samples
(Aarestrup et al., 2000).

Table 1: PCR primers used to probe for the antibiotic resistance genes for the following
antibiotics: bacitracin, chloramphenicol, gentamicin, kanamycin, penicillin, streptomycin,
quinupristin/dalfopristin, tetracycline and vancomycin. (Aarestrup et al., 2000).
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b. Staphylococcus aureus
Staphylococcus aureus is a gram-positive bacterium that is essential to
mammalian normal flora, however, Methicillin resistant Staphylococcus aureus
(MRSA) causes bacterial infections that are highly resistant to penicillin and
contain carbapenem-resistance (Antibiotic 2017). MRSA causes severe flesheating and soft tissue infections and it commonly infects patient’s joints post
orthopedic surgery, therefore, causing complications and delaying the wound
healing process (Bin et. al 2017). S. aureus is on the World Health Organization
(WHO) priority pathogens list for research and development (R&D) of new
antibiotics listed as a high priority pathogen (level 2) (De Freitas, 2013).
S. aureus has increased its resistance to antibiotics by 45% from 1980 to
2000 (Man et al., 2018). MRSA is readily communally acquired, affecting athletes,
those who live in close quarters and patients in hospital settings and health care
settings (Klevens et al., 2007). These infections are often invasive and have a poor
prognosis. In 2005 there were 1598 deaths related to MRSA in the United States
alone (Klevens et al., 2007).
c. Acinetobacter baumannii
Acinetobacter baumannii is an organism commonly found in soil, and is a
rising nosocomial infection (Santajit & Indrawattana, 2016). This organism is a
gram negative, coccobacillus that has been easily transmitted in war zones as it was
prevalent in the Iraq war (Howard, O’Donoghue, Feeney, & Sleator, 2012; Santajit
& Indrawattana, 2016). Earning the nickname

“Iraqibacter”, as it infected

numerous American soldiers (Howard, O’Donoghue, Feeney, & Sleator, 2012).
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A. baumannii is on the World Health Organization (WHO) priority
pathogens list for research and development (R&D) of new antibiotics and is listed
as priority one pathogen (critical priority) (De Freitas, 2013). It infects the skin,
soft tissue, upper respiratory tract and urinary tract (Howard et al., 2012; Santajit
& Indrawattana, 2016). It is a true nosocomial infection that infects
immunocompromised patients with prolonged hospital stays (Howard et al., 2012).
A. baumannii is able to survive on hands for a long duration allowing it to be a
cause of cross contamination in the hospital setting, which is most dangerous in
intensive care units and surgical units (Santajit & Indrawattana, 2016).
d. Pseudomonas aeruginosa
Pseudomonas aeruginosa is a gram negative and rod shaped bacteria
(Santajit & Indrawattana, 2016). It is a part of the gastrointestinal normal flora
(Santajit & Indrawattana, 2016). Pseudomonas commonly infects patients that are
immunocompromised causing severe pneumonia or septicemia; in healthy patients
it is the cause of ear infections and eye infections (Santajit & Indrawattana, 2016).
It is also one of the main contributors to post-surgical infections. P. aeruginosa is
a World Health Organization (WHO) priority for research and development (R&D)
of new antibiotics and is listed as a priority one (critical priority) pathogen (De
Freitas, 2013).
e. Klebsiella pneumoniae
Klebsiella pneumoniae is a gram-negative encapsulated rod-shaped bacteria
that commonly causes pneumonia in patients with alcoholism and diabetes (Ashurst
et al., 2019). K. pneumoniae is colonizer of the GI tract and nasopharynx (Ashurst
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et al., 2019). K. pneumoniae is known to colonize the GI tract due to reoccurring
antibiotic treatment, leaving behind antibiotic resistant K. pneumoniae (Ashurst et
al., 2019). K. pneumoniae is a part of the family Enterobacteriaceae, therefore, it
is also on the WHO priority pathogens list for R&D of new antibiotics and is listed
as a priority one (critical priority) pathogen (De Freitas, 2013; Santajit &
Indrawattana, 2016 ).
f. Enterobacter aerogenes
Enterobacter aerogenes is also a gram-negative rod-shaped bacteria
(Davin-Regali et al., 2015). It readily impacts patients who are utilizing ventilators
and is most commonly transmitted within the intensive care unit (Davin-Regali et
al., 2015).

E. aerogenes is a part of the family Enterobacteriaceae, therefore, it

is also on the WHO priority pathogens list for R&D of new antibiotics and is listed
as a priority one (critical priority) pathogen (Davin-Regali et al., 2015; De Freitas,
2013; Santajit & Indrawattana, 2016 ).
Introduction to Antibiotics and Alternative Treatment Options
Antibiotics are commonly derived from fungi, actinomycetes or bacteriotoxins.
They work by either halting growth/proliferation within the host or by causing bacterial
apoptosis (Saccucci et al. 2018). These drugs can target different parts of the microbial life
cycle in various ways, such as disrupting the bacteria’s transcriptional (DNA synthesis)
and translational material (RNA synthesis), as well as disrupting: bacterial enzymatic
function, cell wall permeability and protein synthesis (Saccucci et al. 2018). Thus, bacterial
growth and proliferation is inhibited.
Antibiotics are prescribed to humans and animals (livestock). Animals farmed for
18

consumption are given antibiotics to gain weight as well as to assure they do not spread
disease (Bischoff et al. 2016). However, they spread the resistance to those who eat
antibiotic treated meat and produce (Bischoff et al. 2016). In South Africa, antibiotic
medications are sold over the counter for personal use and for livestock. These antibiotic
prescriptions are a free for all in many third world countries, which is a large contributing
factor to the prevalence of MDR organisms (Van den Honert, et al. 2018). Replacing
antibacterial treatment with emerging natural remedies may reduce the further spread of
antimicrobial resistance (Bischoff et al. 2016). Evidence has shown that medicinal plants
exhibit antibacterial properties in livestock. In Switzerland farmers utilize homemade
chemical extracts of marigold flowers, stinging nettle, chamomile and coffee as
antimicrobials for their livestock (Bischoff et al. 2016). These chemical extracts have been
shown to be effective on gastrointestinal, metabolic and epidermal infections when tested
by veterinarians in Europe (Bischoff et al. 2016).
Natural Remedies and Previous Studies
Due to the prevalence of antibiotic resistant microorganisms and lack of treatment
options, there is a high demand to research alternative treatment options to circumvent
antibiotic resistance. Researchers have discovered that essential oils were able to reverse
effects of antibiotic resistance when administered in conjunction with antibiotics. This in
vitro study utilized antibacterial resistant bacteria from patients whom were unresponsive
to antibiotic treatment (Lahmar et al. 2017).
Additionally, isolated bacteriocins have been utilized to treat infections.
Bacteriocins are natural anti-bacterial toxins released by bacteria, specifically lactic acid
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bacteria (Bin et. al 2017). Recent evidence has shown that bacteriocins from Lactobacillus
rhamnosus have the ability to halt antibiotic resistant Staphylococcus aureus induced knee
implant infections in a rabbit model (Bin et. al 2017). Staphylococcus aureus form bacterial
biofilms, as they contain highly adhesive proteins that make infections very difficult to
treat. Therefore, these bacteriocins have been shown to inhibit gram positive bacterial
infections, as they are highly water soluble, which can be utilized in further studies (Bin
et. al 2017). Additionally, evidence has shown that the natural oils, Pistacia lentiscus,
Teucruim ramosissimum and Pituranthos chloranthus, coupled with antibiotic treatments
are singularly effective in arresting bacterial growth of resistant bacteria (Lahmar et al.
2017). Amoxicillin, when coupled with essential oils, was actually able to decrease
MRSA’s resistance to the antibiotics (Lahmar et al. 2017). The essential oils T.
ramosisimum, P. chloranthus and P. lentiscus are made up of chemicals that are thought to
be antimicrobial due to their ability to inhibit bacteria, when coupled with antibiotics, and
their ability to reverse antibiotic resistant nosocomial bacterial growth alone (Lahmar et al.
2017). The antibacterial components they postulate are responsible for this antibacterial
resistance reversal effect include: β-eudesmol, limonene, p-Cymene, 1,6- germacradien-5ol, α-pinene, cedreanol, β-caryophyllene and sabinene (Lahmar et al. 2017). These
compounds may be promising components in future antibiotics; however, we do not know
if microorganisms will be able to mutate and resist the synergistic effect of essential oils
and antibiotics (Lahmar et al. 2017).
Additionally, theaflavins, catechins, and epicatechins derived from black tea and
green tea have been found to have antibacterial properties (Betts et al. 2011; De Oliveira
et al. 2015). Stenotrophomonas maltophilia and Acinetobactor baumannii are hospital
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acquired antibiotic resistance bacteria. Recent evidence has shown that polyphenols,
theaflavins and epicatechin derived from black tea exhibit potential antibacterial properties
against S. maltophilia and A. baumanni (Betts et al. 2011).
Furthermore, ethanol extracts from plants have shown antibacterial properties. The
plants include green tea leaves, cinnamon bark, licorice root and elderberry flowers
(Antolak et al. 2017). Evidence has shown that the plants listed above that contain ethanol
extracts with preservative-like properties can actually inhibit the preservative resistant,
opportunistic, infectious agents Asia bogorensis and Asia lannensis, which are gramnegative bacteria that contaminate soft drinks as well as other products (Antolak et al.
2017). These bacteria are able to grow in anoxic environments and are resistant to present
preservatives: potassium sorbate, sodium benzoate and dimethyl dicarbonate (Antolak et
al. 2017). However, the elderberry extract was able to slow the growth of the A. lannensis
and A. bogorensis bacteria and green tea leaves, cinnamon and licorice extracts showed a
statistically significant ability to halt bacterial growth in the beverage in this study (Antolak
et al. 2017). Therefore, these natural extracts may be able to be used in preservations,
pushing us away from antibacterial use that continues to add to the epidemic of resistant
microorganisms (Antolak et al. 2017).
Alternative Treatment using Catechin EGCG-S from Camelia sinesis (Green Tea)
Evidence has shown that catechins found in green tea (Camellia sinensis), including
Epigallocatechin-3-gallate (EGCG), Epicatechin (EC), Epicatechin-3-Gallate (ECG) and
Epigallocatechin (EGC) are all catechin flavonoids that are known for their antiinflammatory and antimicrobial processes. Shown in Figure 2, EGCG contains a longer
carbon chain and is more stable than the other catechins.
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Additionally, epigallocatechin-3-gallate stearate (EGCG-S), which is EGCG,
esterified is shown in Figure 3. EGCG interacts with bacterial transcription potentially
increasing antibiotic permeability (Serra, Mika, Richter, & Hengge, 2016; Xiong et al.,
2017; Zaveri, 2006). However, EGCG is not stable; more stable lipophilic modification of
EGCG derivatives were synthesized yielding the compound shown in Figure 5. EGCG-S
is a more stable derivative in vitro and has been shown to inhibit bacteria secondary to
inducing endogenous oxidative stress and decreasing biofilm formation (Xiong et al.,
2017;Paschalis et al., 2019). In this study, we are studying the potential synergistic effect
of epigallocatechin-3-gallate stearate in conjunction with antibiotics on the ESKAPE
bacteria and E. faecalis.

Figure 2: Molecular Structure of EC, ECG, EGC and EGCG (Laishun et al, 1997).

22

Figure 3: Esterification of EGCG-S (Ali et al., 2012)

Figure 4: Molecular Structure of EGCG-S (Ali et al., 2012)
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Objectives of Study
The research objectives are as follows:
1. Determine the Minimum Inhibitory Concentration (MIC) of EGCG-S on the
growth and viability of ESKAPE bacteria
2. Determine the MIC of EGCG-S on the ESKAPE pathogens’ biofilm
3. Study the potential synergistic effect of EGCG-S with selected antibiotics
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Materials and Methods
Experimental Set Up Standard Procedure
The Biosafety Level 2 (BSL-2) hood was wiped down with 10% bleach and
exposed to ultraviolet light for 20 minutes before and after experiment.
Media Preparation
Seven types of media were used in this study: Brain Heart Infusion Agar (BHI-A),
Brain Heart Infusion Broth (BHI-B), Mueller Hinton Agar (MHA), Nutrient Agar (NA),
Nutrient Broth (NB), Tryptic Soy Agar (TSA) and Tryptic Soy Broth (TSB). Each medium
was prepared according to manufacturer’s protocol and autoclaved accordingly. Each
individual agar medium was poured into plates and left in sterile hood overnight to solidify.
The following day the solidified agar plates were packaged in a plastic sleeve, taped,
labeled and stored at 4˚C.
Organism

Optimal Medium

Enterococcus faecium (E. faecium)

BHI-A & BHI-B

Enterococcus faecalis (E. faecalis)

NA & NB

Staphylococcus aureus (S. aureus)

NA & NB

Klebsiella pneumoniae (K.pneumoniae)

NA & NB

Pseudomonas aeruginosa (P.aeruginosa)

NA & NB

Acinetobacter baumannii (A. baumanniii)

TSA & TSB

Enterobacter aerogenes (E. aerogenes)

NA & NB

Table 2: The optimal media to maintain and grow each bacterium
a. Brain Heart Infusion Agar:
BHI-A from Criterion Dehydrated Culture Media was prepared combining
49.7gm of BHI-A medium with 1L of deionized water. The medium was
autoclaved for 15 minutes at 121˚C. Then BHI-A medium was poured into
mono plates in order to assure optimal growth of E. faecium, which was
inoculated using aseptic techniques and continuous streak method every two
weeks to maintain pure culture.
b. Brain Heart Infusion Broth:
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BHI-B from Criterion Dehydrated Culture Media was prepared combining
37.0gm of BHI-B medium with one liter of deionized water. The medium was
autoclaved for 15 minutes at 121˚C. Ten milliliters (10 mL) of BHI-B medium
were then aliquoted into multiple test tubes to be used for further experiments.
c. Mueller Hinton Agar:
MHA from Carolina Biological Supply was prepared by weighing out 38gm of
the medium in 1L of deionized water. The medium was autoclaved for 15
minutes at 121˚C. The MHA medium was poured into mono plates to be used
for Kirby-Bauer Disk Diffusion.
d. Nutrient Agar:
NA from Criterion Dehydrated Culture Media combining 20.5 gm of medium
in 1L of deionized water. The medium was autoclaved for 15 minutes at 121˚C.
After retrieval from the autoclave, of NA was poured into mono plates in order
to assure optimal growth of E. faecalis, S. aureus, E. aerogenes, K. pneumoniae,
and P. aeruginosa, which were inoculated using aseptic techniques and
continuous streak method every two weeks to maintain pure culture.
Additionally, NA was used during the Rapid Agar Plate Assay (RAPA).
e. Nutrient Broth:
NB from Ward’s Science was prepared combining 8 gm of medium in 1L of
deionized water. The medium was autoclaved for 15 minutes at 121˚C. After
retrieval from the autoclave, 5 mL of NB were aliquoted into multiple test tubes
in preparation for overnight cultures of E. faecalis, S. aureus, E. aerogenes, K.
pneumoniae, and P. aeruginosa.
f. Tryptic Soy Agar Preparation
TSA from Carolina Biological Supply was prepared using 30 grams of TSA
powder media and 1L of deionized water. The medium was autoclaved for 15
minutes at 121˚C. The TSA medium was poured into mono plates to assure
optimal growth of A. baumannii, which was inoculated using aseptic techniques
and continuous streak method every two weeks to maintain pure culture.
e. Tryptic Soy Broth Preparation
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TSB from Carolina Biological Supply was prepared using 30 gm of TSB media
and 1L of deionized water. The medium was autoclaved for 15 minutes at
121˚C. After retrieval from the autoclave, 5 mLs of TSB medium were
aliquoted into multiple test tubes for further use.
Bacteria utilized and maintained throughout this study
a. Gram-positive bacteria used in this research:
Enterococcus faecium (E. faecium), Enterococcus faecalis (E. faecalis), and
Staphylococcus aureus (S. aureus).
b. Gram-negative bacteria used in this research:
Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumannii (A.
baumannnii), Pseudomonas aeruginosa (P. aeruginosa) and Enterobacter
aerogenes (E. aerogenes).
Utilizing a loop full of sterile stock culture every two weeks to maintain ESKAPE
microorganisms in their corresponding agar medium shown in Table 2 via a continuous
streak. Then placed in an incubator at 37˚C for 24 hours. Each plate was wrapped in
parafilm and stored at 4˚C for future use. Bacterial purity was checked periodically by
using simple or Gram stain to confirm purity. In cases of contamination, a discontinuous
steaking method was used to isolate colonies to start a new stock.
Overnight Cultures
One day prior to each experiment, overnight cultures were made utilizing sterile
cultures from the continuous streaks that were maintained biweekly. Each bacterium was
resuspended utilizing a sterile plastic loop from Argos Technologies in NB, TSB and BHIB according to each bacteria is optimal growth media shown in Table 2 above at 37˚C with
continuously shaking at 250 rpm.
Staining Techniques
a. Simple Stain
The protocol for simple stain used in this study is described in the Fifth Edition of
Microbiology Laboratory Manual (Lee et al., 2018). Methylene blue was used for
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simple stain to determine purity and morphology of all organisms in this study.
Inoculations were retrieved from each bacterium is overnight culture.
b. Gram Stain
The Gram stain was used to differentiate between Gram-positive and Gramnegative bacteria, as well as to determine the morphology of the bacteria. The Gram
stain protocol was performed as described in the Fifth Edition of Microbiology
Laboratory Manual (Lee et al., 2018). Each bacterium used was freshly prepared
overnight culture.
Polymerase Chain Reaction (PCR) to Amplify DNA for Sequence Analysis
The purity of each culture was determined utilizing the following molecular
mechanisms. The procedure mirrored the Fifth Edition of Microbiology Laboratory
Manual (Lee et al., 2018). Sterile techniques were used throughout entire procedure.
a. DNA extraction procedure described as follows:
i. First a heat block was set to 100 ˚C and an ice bath was made.
ii. For each sample 5% Chelex was vortexed for 60 seconds then 100 uL was
aliquoted in six 1.5 mL labeled microcentrifuge tube.
iii. Then 500 uL of each bacterium’s overnight culture was placed into the
respective 1.5 mL microcentrifuge tube with the Chelex. Then each tube
was vortexed for 30 seconds.
iv. The six microcentrifuge tubes were placed on the heating block for ten
minutes and then immediately placed on the ice bath for one minute.
v. Samples were retrieved the samples from the ice bath
vi. Each tube was vortexed for 30 seconds prior to being placed in the
microcentrifuge for one minute at maximum speed (13,000 rpm/17,000g)
vii. The supernatant containing the DNA extraction of each individual bacteria
was then carefully pipetted into a newly labeled 1.5 mL microcentrifuge
tube and kept on the ice bath.
b. Determining the concentration and purity of each sample using
NanoDropâ Readings:
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i. The NanoDrop ND-1000 was blanked with 1.5 μL of sterile deionized water
before and after each sample was tested.
ii. 1.5 μL of each sample was pipetted onto the ND-1000 pedestal using a P10 micropipette. DNA concentration and purity was recorded in ng/μL and
using A260/280 ratio, respectively.
c. PCR preparation:
i. The following materials were utilized to for 16S amplification: Forward
primer 27F (5’- AGA GTT TGA TCC TGG CTC AG-3’) and reverse
primer 1492R (5’- ACG GCT ACC TTG TTA CGA CTT-3’)
ii. 20 μL of 2X Taq DNA Polymerase Master Mix (DNA Taq polymerase,
dNTPs, sterile deionized water, buffer and MgCl2)
iii. 2 μL of 10 μM 27F forward primer
iv. 2 μL of 10 μM 1492R reverse primer
v. 14 μL of nuclease-free water
vi. 2 μL of microbial DNA
vii. The six samples were placed on ice until placed in the thermal cycler.
d. Thermal Cycler Program:
i. The thermal cycler program utilized is as follows: 1. 95 ˚C for one minute
in order to denature the double stranded DNA. 2. 25 cycles of the following:
95 ˚C (10 seconds), 55 ˚C (10 seconds), and 72 ˚C (10 seconds). 3. 72 ˚C
for 10 minutes to ensure to resynthesize the DNA molecules.
ii. PCR products were stored in -20 ˚C refrigerator.
e. Agarose Gel & Gel Electrophoresis
i. 0.4gms of agarose powder was combined with 40 mL of electrophoresis
buffer and then placed into microwave until powder was fully dissolved.
Once heated 4 μL of SYBR SAFE was added utilizing a P10 micropipette.
ii. Comb was placed into the gel box, followed by the liquid agarose gel.
iii. Once the gel solidified, 10 μL from each individual PCR product from
step 4.c. was placed into a six new microcentrifuge tubes and 2 μL of
Bromophenol Blue dye was added to each tube.
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iv. 12 μL of each sample was loaded into its own individual well. The first and
last were loaded with12 μL of the DNA ladder.
Preparation of Green Tea Polyphenols:
Green Tea Polyphenol EGCG-S (U.S. Patent #: 20120171423) was purchased from
Camellix LLC, Augusta, GA. EGCG-S stocks were prepared in concentrations of 10x of
250μg/ml and 10x of 500μg/ml.
Kirby-Bauer Disk Diffusion:
An overnight culture of each of the organisms (ESKAPE) was prepared. Individual
loops were utilized to swab each of the seven organisms’ sterile culture and then plated to
form a continuous streak on MHA plates for each bacterium. This protocol was
completed twice for each trial. Trial one antibiotics were used only as treatment. Trial
two antibiotics were used in conjunction with 25 μL of EGCG-S (250 μg/mL). Three
replicates were completed for each trial.
Seven of the plates were stamped with the following antibiotic disks: Bacitracin
(B10), Chloramphenicol (C30), Erythromycin (E15), Polymyxin B (PB300), Tetracycline
(TE30), and Vancomycin (VA30).
The seven remaining plates were stamped with the same antibiotics and 25 μL of
EGCG-S (250 μg/mL) was infused onto the filter disk at room temperature.
The plates were placed into the incubator at 37 ˚C for 48 hours. The zone of
inhibition (ZOI) was measured in millimeters (mm) after 24 and 48 hours respectively.
Percentage of inhibition to test the potential synergistic effect of antibiotics and EGCG-S
was calculated using the following formula.
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Antibiotic

Disk

Abbreviation Resistant

Potency
Bacitracin

Intermediate Susceptible

(R) (mm) (I) (mm)

(S) (mm)

10 μg

B10

<9

9 – 12

> 12

Chloramphenicol 30 μg

C30

< 13

13 – 17

> 17

Erythromycin

15 μg

E15

< 14

14 – 17

> 17

Polymyxin

300 μg

PB300

<9

9 -11

> 11

Tetracycline

30 μg

TE30

< 15

15 – 18

>18

Vancomycin

30 μg

VA30

<9

20-22

>12

Table 3: Kirby Bauer Disk Diffusion Categories
=

𝐴−𝐵
× 100
𝐵

𝐴 = 𝑍𝑂𝐼 𝑜𝑓 𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝐵 = 𝑍𝑂𝐼 𝑜𝑓 𝑅𝑒𝑠𝑝𝑒𝑐𝑡𝑖𝑣𝑒 𝐴𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
Equation 1: % of ZOI increase/ decrease
Growth Curve of Microorganisms:

Standard Growth Curve of the ESKAPE

organisms and The Effect of EGCG-S on Growth of ESKAPE Microorganisms
Overnight cultures were prepared and diluted using the specific broth for each
bacterium with an Optimal Density (OD) of 0.1 at 600nm. A 48 well plate was used to
prepare the seven microorganisms and was placed in a shaking incubator at 125 rpm at
optimal temperature. Multi-plate reader, TECAN InfiniteM200 Pro, was used to monitor
the growth at 600nm every hour for 10 hours with a final reading taken at 24 hours. The set
up for this study is shown in Table 4. The control contained 450 μL of the diluted overnight
culture and 50 μL of its respective media to determine the standard growth curve for each
microorganism shown in Table 2. Two treatment concentrations were utilized to study the
effects of EGCG-S on bacterial growth and proliferation: 250 μg/mL (T1) and 500ug/ml
(T2) shown in Table 4. The growth curve was plotted using the mean of duplicates with
the Standard Deviation (SD) and plotted with OD (y-axis) vs. Time (x-axis). The
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generation time was calculated for each bacterium during the exponential growth phase
(three to five hours for each bacteria). The equation used of determine generation time is:
g = (log10 N1 – log10N0) / log102.to determine the doubling time required for each organism
in different conditions.
450 μL of E.

450 μL of E.

450 μL of

450 μL of

450 μL of

450 μL of

450 μL of E.

Same as to

faecium +

faecium +

E.faecium +

A.baumannii

A.baumannii

A.baumannii

faecalis + 50 μL

the left.

50 μL of

50 μL of

50 μL of 500

+ 50 μL of

+ 50 μL of

+ 50 μL of

of NB(Control)

BHI-B

250 μg/mL

μg/mL

NB

250

500

(Control)

EGCG-S

EGCG-S

(Control)

EGCG-S

Same

as

above

Same

as

above

Same

as

above

Same

as

above

μg/mL

Same

μg/mL

EGCG-S

as

above

Same

as

above

450 μL of E.

Same as to

faecalis + 50 μL

the left

of 250 μg/mL
EGCG-S
450 μL of S.

450 μL of S.

450 μL of S.

450 ul of P.

450 μL of P.

450 μL of P.

450 μL of E.

Same as to

Aureus + 50

Aureus + 50

Aureus + 50

aeruginosa +

aeruginosa +

aeruginosa +

faecalis + 50 μL

the left

ul of

μL of 250

μL of 500

50 μL μg/mL

50 μL of 250

50 μL of 500

of 500 μg/mL

μg/mL

μg/mL

of NB

μg/mL

μg/mL

EGCG-S

NB

(Control)

EGCG-S
Same

as

Same

EGCG-S
as

Same

(Control)
as

Same

EGCG-S
as

Same

EGCG-S
as

Same

as

TSB

above

above

above

above

above

above

450 ul of K.

450 ul of K.

450 ul of K.

450 ul of E.

450 ul of E.

450 ul of E.

TSB

pneumoniae

pneumoniae

pneumoniae

aerogenes +

aerogenes +

aerogenes +

Treatment 1

+ 50 μL of

+ 50 μL of

+ 50 μL of

50 μL of NB

50 μL of 250

50 μL of 500

NB

250 μg/mL

500 μg/mL

(Control)

μg/mL

μg/mL

(Control)

EGCG-S

EGCG-S

EGCG-S

EGCG-S

Same
above

as

Same
above

as

Same
above

as

Same
above

as

Same
above

as

Same
above

as

NA
+

NA

+

Treatment
1

TSB
Treatment 2

+

NA

+

Treatment
2

Table 4: 48 well plate set up: the control contained 450 ul of the diluted overnight
culture and 50 ul of its respective media this was the control (standard growth curve) for
each microorganism. Two treatment concentrations were utilized to study the effects of
EGCG-S on bacterial growth and proliferation: 250 µg /mL (T1) and 500 µg /ml (T2)
shown above.
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Effect of Green Tea Polyphenol EGCG-S on Biofilm
Two 48 well plates were set up identically to Table 4 (growth curve table) and then
placed in the incubator for 72 hours at 37 ˚C. Each micropipette tip used during this
procedure was discarded after each reagent was placed into a single well. After 72 hours,
the plates were retrieved from the incubator and the following two methods were used to
quantitatively study the biofilm formation:
a. Crystal Violet Assay
i. Each well was aspirated and then washed with 250 μL of 1 x Phosphate
Buffered Saline (PBS) three times.
ii. Crystal Violet (0.1%) was added into each well and allowed to sit for 30
minutes. After 30 minutes, the dye was aspirated.
iii. Each plate was inverted and incubated overnight on sterile absorbent pad at
room temperature (25 ˚C) for 24 hours.
iv. The wells were allowed to air dry for 24 hours. Each wall was cleaned
utilizing PBS, 30% acetic acid and sterile cotton swabs.
v. Then 500 μL of 30 % acetic acid was placed into each well.
vi. The Multi-plate reader, TECAN InfiniteM200 Pro, was used to measure the
biofilm formation at the OD of 595nm.
b. Resazurin Assay
i. Each well was aspirated and then washed with 250 μL of 1 x Phosphate
Buffered Saline (PBS) three times.
ii. Then 200 μM of Resazurin working solution (original stock is 2mM, 5 mg
of Resazurin powder + 10 mL of PBS) was added to each well.
iii. The 48 well plate was then covered with aluminum foil and placed in the
freezer to incubate at 4 ˚C for 24 hours.
iv. The Multi-plate reader, TECAN InfiniteM200 Pro, was then used to
measure fluorescence with an excitation wavelength of 560nm and
emission wavelength at 590nm.

33

Pre and Post Application of EGCG-S Using Rapid Agar Plate Assay (RAPA)
a. Pre-Application of EGCG-S
Seven specific agar plates for each of the ESKAPE organisms as seen in
Table 2 were utilized. Then 100 μL of 250 μg/mL of EGCG-S was then applied to
each plate and left to sit for one hour.
All microorganisms were diluted to an OD600nm reading of 0.10 and diluted
to 10-6 and 10-8 using sterile DI H2O. The dilution factor varied among species. The
dilution factor for all samples was optimized to determine CFUs in a countable
range. Then 100 μL of each bacteria from the optimal dilution factor was then added
to its corresponding labeled and treated agar plate. Samples were spread throughout
the entirety of the agar and then placed in the incubator at 37 ˚C for 24 hours. The
CFUs were counted after the 24 hour incubation period and percent (%) of
inhibition was calculated.
b. Post-Application of EGCG-S
First 100 μl of each of the ESKAPE organism dilutions from 11a. were
plated on their respective agar plates as seen in Table 2 and allowed to air dry for
five minutes. Then 100 μL of 250μg/mL of EGCG-S was obtained utilizing a P1000
micropipette and applied onto the agar plates. EGCG-S was spread onto the entire
plate utilizing a sterile plastic loop. Placed were placed into the incubator at 37 ˚C
for 24 hours. The CFUs were counted after the 24 hour incubation period and % of
inhibition was calculated.
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =

(𝐶𝐹𝑈 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐶𝐹𝑈 𝑜𝑓 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
× 100%
𝐶𝐹𝑈 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙

Equation 2: CFUs were counted for methods 11a-c the following day. Percent inhibition
was calculated utilizing the formula above.
Fluorescence Microscopy using BacLight™ Live and Dead Assay
A sterile loop full of each individual ESKAPE bacteria was retrieved from the
EGCG-S solution post application trial and smeared onto its corresponding labeled slide
(ie. Kp Post-Treatment). A control for each bacterial sample was smeared onto a glass slide
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corresponding to the bacteria. Fourteen slides in total were prepared in a dark room: seven
were controls and seven of the bacteria that were treated with the post application of
EGCG-S. Ten μL of Syto®9 dye from the LIVE/DEAD® BaclightTM Kit was added to
each slide with a cover slip placed on top. Slide tray was covered with aluminum foil and
left at room temperature for 10 minutes. Each slide was viewed under 400X total
magnification using a ZEISS fluorescence microscope.
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Results and Discussion
In this study, seven microorganisms were used:

Gram-positive Bacteria:

Enterococcus faecium/faecalis (E. faecium/faecalis), Staphyloccoccus aureus (S.aureus);
Gram-negative

Bacteria: Acinetobacter baumanni (A. baumanni), Pseudomonas

aeruginosa (P. aeruginosa), Klebsiella pneumoniae (K. pneumoniae) and Enterobacter
aerogenes (E. aerogenes).

To determine if antibiotics and EGCG-S worked

synergistically, the following experiments have been performed.
Determination of bacterial purity:
5a. E. faecium
5b. E. faecalis

5d. K. pneumoniae

5e. A. baumannii

5c. S. aureus

5f. P. aeruginosa

5g. E. aerogenes

Figure 5a-5g: Gram Stain of The ESKAPE Bacteria and E. faecalis
a. E. faecium:
i. In Figure 5a, the Gram Stain of E. faecium shows that it is a coccus
(round) shaped bacteria that is found in pairs and clusters. The
purple stained cells indicate that E. faecium is a gram-positive
bacterium.
b. E. faecalis:
i. In Figure 5b: The Gram Stain of E. faecium is a cocci (round) shaped
bacteria that is found in pairs and clusters. The purple stained cells
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indicate that E. faecium is a gram-positive bacterium and no
contaminants are present.
c. S. aureus:
i. In Figure 5c: The Gram Stain of S. aureus is cocci (round) shaped
bacteria that is found in grape like structure, the purple stained cells
indicate that S. aureus is a gram-positive bacterium as it is stained
purple.
d. K. pneumoniae:
i. In Figure 5d: The Gram Stain shows K. pneumoniae, a
bacillus (rod) shaped bacterium that contains a capsule surrounding it
(encapsulated). The cells are stained pink, indicating it is a gramnegative bacterium.
e. A. baumannii:
i. In Figure 5e: The Gram Stain shows that A. baumannii is a
coccobacillus that did not retain the purple Gram stain dye.
Indicating it is a gram-negative bacterium.
f. P. aeruginosa:
i. In Figure 5f: The Gram Stain shows that P. aeruginosa is a rod-shaped
bacterium. The cells are stained pink indicating it is a gram-negative
bacterium as its thick peptidoglycan wall will not retain the dye.
g. E. aerogenes:
i. In Figure 6g: The Gram Stain shows that E. aerogenes is a rodshaped encapsulated bacterium. The cells are stained pink,
indicating that it is a gram-negative bacterium.
Each bacterium was homogeneous as determined by the Gram Stain. Thus, we can
determine that our stock cultures are pure and no contaminants were present.
DNA extraction and NanoDropÒ Readings:
DNA extracted from E. faecium, E. faecalis, S. aureus, K. pneumoniae, A.
baumannii, and E. aerogenes were analyzed. To assure that enough DNA was extracted
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for PCR, DNA concentration was measured. Additionally, purity was determined utilizing
the NanoDrop absorbance ratio of 260nm over 280nm; a ratio that is close to 1.80 is
considered pure (In et al., 2007).
Organism

DNA concentration (ng/uL) A260/280 Ratio

E. faecium

295.7

1.78

E. faecalis

289.9

1.78

S. aureus

292.1

1.74

K. pneumoniae
A. baumannii

323.8
1327.1

1.67
1.37

P. aeruginosa

343.9

1.76

E. aerogenes

279.6

1.74

Table 5: DNA concentration is measured in ng/uL. DNA purity was analyzed utilizing
the absorbance ratio of 260nm over 280nm.
The DNA concentrations for all of the bacteria tested ranged from 279.6 ng/uL –
1327.1 ng/uL seen in Table 5. The purest DNA according to A260/280 ratios were
extracted from E. faecium and faecalis both containing a ratio of 1.78 followed by E.
aerogenes, S. aureus, K. pneumoniae, A. baumanni and E. aerogenes with 1.74, 1.74, 1.67,
and 1.37 respectively.

Gel Electrophoresis:
PCR products were analyzed utilizing gel electrophoresis to ensure 16s rRNA gene
amplification was present prior to DNA sequencing. The 16s rRNA gene band appeared in
all of the organisms tested:

E. faecium, E. faecalis, S. aureus, K. pneumoniae, A.

baumannii, and E. aerogenes shown in Figure 6. The DNA samples were successfully
amplified with 16s primers. A. baumannii, E. faecium and S.aureus contained faint bands
going from light to dark, respectively. E.aerogenes, E. faecalis and K. pneumoniae bands
were bright. DNA concentration of A. baumanni was high with a reading of, 1327.1 ng/uL,
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however, it contained the faintest band on the gel. Since the band is visible, further DNA
sequencing was carried out. P. aeruginosa is not shown.

HL
Ab
Ea
Ef
Efm
Kp
Sa
HL

HiLo DNA Marker
A. baumannii
E. aerogenes
E. faecalis
E. faecium
K. pneumoniae
S. aureus
HiLo DNA Marker

Table 6: Gel Electrophoresis Key:
Showing which well corresponds with
each bacterial PCR product or DNA
ladder. The HiLo DNA ladder used to
identify the 16s rRNA gene.
Figure 6: Gel Electrophoresis of PCR products of A. baumannii, E. aerogenes, E. faecalis
E. faecium, K. pneumoniae, S. aureus and a HiLo DNA marker on the left and right for
reference.
DNA sequencing:
DNA sequencing was completed for all of the bacteria in this study E. faecium, E.
faecalis, S. aureus, A. baumanni, P. aeruginosa, K. pneumoniae and E. aerogenes. The
forward sequences were analyzed utilizing the Basic Local Alignment Search Tool
(BLAST) for each of the bacterium to determine if their sequences matched their species
on the BLAST database. E values that are closest to zero or less than zero indicate that it
is a significant match. Red indicates the highest alignment scores shown on the right
Figures 7a-7g.
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Figure 7a: BLAST Query for E.faecium
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Figure 7b: BLAST Query for E. faecalis
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Figure 7c: BLAST Query for S. aureus
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Figure 7d: BLAST Query for A.baumannii
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Figure 7e: BLAST Query for P. aeruginosa
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Figure 7f: BLAST Query for K. pneumoniae.
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Figure 7g: BLAST Query for E. aerogenes.
The results confirmed the purity of the bacterial stocks. E. faecalis, S. aureus, K.
pneumoniae, A. baumannii, P. aeruginosa and E. aerogenes all have E values of 0,
therefore our stock cultures DNA sequences significantly matched with their species on
BLAST. With percent identify of 89.10%, 100%, 95.72%, 97.50%, 97.51% and 93.08%,
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respectively. E. faecium had an E value of 6e-123 and 81.85% identity, which is less
significant, however, we can still determine that our culture is mainly pure.
Kirby Bauer Disk Diffusion Test to Profile the Effect of Different Antibiotics and
EGCG-S on ESKAPE
The Kirby-Bauer disk diffusion test was used to determine the susceptibility of each
bacteria to antibiotics alone and to compare the potential synergistic effect of EGCG-S and
antibiotics. The zone of inhibition (ZOI) diameter was measured over the antibiotic disk in
millimeters (mm) to measure the effectivity or susceptibility of each treatment. The results
are shown in Figures 8a-8g after 24 hours of incubation. The results are shown in Figures
9a-9g after 48 hours of incubation.
8a.

8b.
E. faecalis disk diffusion with and without EGCG-S after
48 hour treatment
30

Zone of Inhibition (mm)
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15
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5
0

8c.

Bacitracin

Chloramphenicol Erythromycin
Polymyxin B
Tetracycline
Antibiotics used without ECGC-S (first bar) and with ECGC-S

Vancomycin

8d.
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8e.

8f.
E. aerogenes disk diffusion with and without EGCG-S after 24
hour treatment

disk diffusion
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after 24
24 hour
hourtreatment
treatment
after

25

20

20

Zone of Inhibition (ZOI)

Zone of
of Inhibition (ZOI)
Zone

25

15
10
5
0

15

10

5

Bacitracin
Bacitracin

Chloramphenicol
Chloramphenicol Erythromycin
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PolymyxinBB
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Tetracycline
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EGCG-S(second
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0
Bacitracin

Chloramphenicol Erythromycin
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8g.
P. aeruginosa disk diffusion with and without EGCG-S after
24 hour treatment
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Intermediate (I)
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Figures 8a-g: Each of the ESKAPE organisms were treated with six different antibiotics
in one trial (left bar above each antibiotic category). The second trial (right bar above each
antibiotic category) utilized the same six antibiotics in combination with 25 µL of 250
µg/mL EGCG-S. This study was repeated three times and the bar graphs contain a mean
of the triplicate and SD after 24 hours.
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9a.

9b.
E. faecium disk diffusion with and without EGCG-S
after 48 hour treatment
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9c.

9d.

9e.

9f.
P. aeruginosa disk diffusion with and without EGCG-S after 48
hour treatment

A. baumanni disk diffusion with and without EGCG-S after 48
hour treatment
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9g.
E. aerogenes disk diffusion with and without EGCG-S after 48
hour treatment

Zone of Inhibition (ZOI)

25
20
15
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5
0
Bacitracin Chloramphenicol Erythromycin Polymyxin B
Tetracycline
Vancomycin
Antibiotic treatment (first bar) and in combination with EGCG-S (second bar)

Resistant (R)

Intermediate (I)

Sensitive (S)

Figures 9a-9g: Each bacteria was treated with six different antibiotics in one trial (left bar
above each antibiotic category). The second trial (right bar above each antibiotic category)
utilized the same six antibiotics in combination with 25 µl of 250 µg/ml EGCG-S.
The results indicate that EGCG-S can increase the ZOI of some antibiotics as shown
in Tables 7-13, thus, increasing the efficacy of the following antibiotics shown in yellow
and green in Tables 7-13.
Enterococcus faecium (E. faecium)
Antibiotics

% ZOI Increase/Decrease

Susceptibility Change

4.54%

SàS

Chloramphenicol (C30)

15.78 %

SàS

Erythromycin (E15)

9.52 %

IàS

150

RàS

7.69%

Sà S

Bacitracin (B10)

Polymyxin B (PB300)
Tetracycline (TE30)

5.26%
Vancomycin (VA30)
SàS
Table 7: The numerical values of the percentage of synergy and status of susceptibility
comparing trial one (solely antibiotics) and trial two (antibiotics in combination with
EGCG-S) on E. faecium.
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Enterococcus faecalis (E. faecalis)
Antibiotics

% ZOI Increase/Decrease

Susceptibility Change

0%

SàS

Chloramphenicol (C30)

7.14 %

SàS

Erythromycin (E15)

20.62 %

IàS

Polymyxin B (PB300)

150 %

RàS

Tetracycline (TE30)

-5.46 %

SàS

Bacitracin (B10)

Vancomycin (VA30)
-2.63 %
SàS
Table 8: The percentage of synergy and status of susceptibility comparing trial one
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour
treatment on E. faecalis.
Staphylococcus aureus (S. aureus)
Antibiotics

% ZOI Increase/Decrease

Susceptibility Change

18.18

Rà R

Chloramphenicol (C30)

15.00%

Rà R

Erythromycin (E15)

10.00%

IàI

Polymyxin B (PB300)
Tetracycline (TE30)

27.27%
-6.89%

IàS
SàS

Bacitracin (B10)

Vancomycin (VA30)
0
Sà S
Table 9: The percentage of synergy and status of susceptibility comparing trial one
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour
treatment on S. aureus.
Klebsiella pneumoniae (K.pneumoniae)
Antibiotics

% ZOI Increase/Decrease

Susceptibility Change

Bacitracin (B10)

86%

RàS

Chloramphenicol (C30)

6%

RàI

Erythromycin (E15)

44%

IàR
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Polymyxin B (PB300)

36%

Sà S

Tetracycline (TE30)

-14%

Ià S

Vancomycin (VA30)

117%

Ià S

Table 10: The percentage of synergy and status of susceptibility comparing trial one
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour
treatment on K. pneumoniae.
Acinetobacter baumannii (A. baumannii)
Antibiotics

% ZOI Increase/Decrease

Susceptibility Change

Bacitracin (B10)

6.95 %

Ià S

Chloramphenicol (C30)

66.66 %

Rà R

Erythromycin (E15)

6.66 %

Ià I

Polymyxin B (PB300)
Tetracycline (TE30)

13.33%
0

Ià S
Sà S

Vancomycin (VA30)

88.88 %

Rà I

Table 11: The percentage of synergy and status of susceptibility comparing trial one
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour
treatment on A. baumannii.
Pseudomonas aeruginosa (P.aeruginosa)
Antibiotics
Bacitracin (B10)
Chloramphenicol (C30)
Erythromycin (E15)

% ZOI Increase/Decrease
0%
16.66 %
0%

Susceptibility Change
RàR
Rà I
Ià I

Polymyxin B (PB300)

42.85 %

IàS

Tetracycline (TE30)
0%
Sà S
Vancomycin (VA30)
0%
Rà R
Table 12: The percentage of synergy and status of susceptibility comparing trial one
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour
treatment on P.aeruginosa.
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Enterobacter aerogenes (E. aerogenes)
Antibiotics
Bacitracin (B10)

% ZOI Increase/Decrease

Susceptibility Change

183.3 %

Rà S

Chloramphenicol (C30)

0.00 %

Rà I

Erythromycin (E15)

88.88 %

Ià R

Polymyxin B (PB300)

155.5 %

Sà S

0%

IàS

Tetracycline (TE30)
Vancomycin (VA30)
No change

100%
Intermediate (I)

IàS
Sensitive (S)

Table 13: The percentage of synergy and status of susceptibility comparing trial one
(solely antibiotics) and trial two (antibiotics in combination with EGCG-S) after 48 hour
treatment on E.aerogenes.
Tables 7-13 are the percent of ZOI increase and status of susceptibility change
comparing trial one and trial two after 48 hour treatment. In Tables 7 & 8 E. faecium and
E. faecalis went from resistant to Polymyxin B to susceptible in combination with EGCGS, with 150% synergistic effect for both organisms. E. faecium and E. faecalis went from
intermediate to susceptible to Erythromycin with 9.52% and 20.62% synergistic effect. S.
aureus, A. baumannii, and P. aeruginosa went from intermediate to susceptible to
Polymyxin B with a 27.27%, 13.33%, and 42.85% synergistic effect, respectively. A.
baumannii went from intermediate to susceptible to bacitracin with a 6.95% synergy, and
for vancomycin, the bacteria went from resistant to intermediate with a 88.88% synergy.
P. aeruginosa went from resistant to intermediate susceptibility to chloramphenicol with a
16.66% synergy.
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The Effect of EGCG-S on Bacterial Growth
ESKAPE growth without treatment (control) and with EGCG-S at 500 µg/mL and 250
µg/mL, respectively, was monitored for 10 hours in a 48 well plate with a final 24 hour
reading. The absorbance was measured every hour at an OD 600nm. The results are shown
in Figures10a - 10g.
Bacterial standard growth curves contain a lag phase, exponential phase and a
stationary phase. This was observed for all of the ESKAPE bacteria and E. faecalis . Once
the nutrients in the media were depleted, the bacteria entered stationary phase. The
exponential phase was seen in most of the bacteria between 1-5 hours, as seen in Figures
10a-10g.

E. faecium

Absorbance (600nm)

1.4
1.2
1
0.8

Control

0.6

250 ug/ml

0.4
0.2

500 ug/ml

0
0

1

3

5

7

9

24

Time (hr)

Figure 10a: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of E.
faecium at both µg/mL and 500 µg/mL
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E. faecalis
Absorbance (600 nm)

0.14
0.12
0.1
0.08

Control

0.06
0.04

250 ug/ml

0.02

500 ug/ml

0
0

1

3

5

7

9

24

Time (hr)

Figure 10b: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of E.
faecalis at both 250 µg/mL and 500 µg/mL

S. aureus
Absorbance (600 nm)

0.6
0.5
0.4
Control

0.3

250 ug/ml

0.2

500 ug/ml
0.1
0
0

1

3

5

7

9

24

Time (Hr)

Figure 10c: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of S. aureus
at both 250 µg/mL and 500 µg/mL
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Absorbance (600nm)

K. pneumoniae
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

Control
250 ug/ml
500 ug/ml
0

1

3

5

7

9

24

Time (Hr)

Figure 10d: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of K.
pneumoniae at both 250 µg/mL and 500 µg/mL

A. baumannii

0.7

Absorbance (600nm)

0.6
0.5
0.4
Control

0.3
0.2

250 ug/ml

0.1

500 ug/ml

0
-0.1
-0.2

0

1

3

5

7

9

Time (hr)

Figure 10e: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of A.
baumannii at both 250 µg/mL and 500 µg/mL.
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P. aeruginosa
Absorbance (600 nm)

0.7
0.6
0.5
0.4
0.3

Control

0.2

250 ug/ml
500 ug/ml

0.1
0
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1

3

5
Time (hr)
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9

24

Figure 10f: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of P.
aeruginosa at both 250 µg/mL and 500 µg/mL.

E. aerogenes

0.6

Absorbance (600 nm)

0.5
0.4
Control

0.3

250 ug/ml

0.2

500 ug/ml

0.1
0
0

1

3

5

7

9

24

Time (hr)

Figure 10g: The blue line is the control, 250 µg/mL of EGCG-S (red) and 500 µg/mL of
EGCG-S (green). EGCG-S was shown to inhibit the growth and proliferation of E.
aerogenes at both 250 µg/mL and 500 µg/mL.
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Generation time was calculated in minutes based on the following equation: g = (log10
N1 – log10N0) / log102. If the generation time increases in the presence of EGCG-S, this
indicates the polyphenol was able to slow growth and proliferation of the bacteria in
comparison to their standard curve shown in blue in Figures10a-10g. The generation time
was calculated utilizing Equation 2 and is in Table 14.
The results indicated that EGCG-S potentially inhibited the growth at both 250 µg/mL
and 500 µg/mL of all the ESKAPE bacteria. The 250 µg/mL concentration was more
effective in inhibiting bacterial growth. EGCG-S was most effective in inhibiting S. aureus
and E. aerogenes.
Organism
E. faecium

Control
112.2 (3-5 hours)

T1 (250 µg/mL)
-1219 (3-5 hours)

T2 (500 µg/mL)
-320.0 (3-5 hours)

E. faecalis

1025 (3-5 hours)

-3621 (3-5 hours)

-405.8 (3-5 hours)

S. aureus

263.0 (3-5 hours)

-5189 (3-5 hours)

635.7(3-5 hours)

K. pneumoniae

117.9 (1-3 hours)

-697.4 (1-3 hours)

-56.98 (1-3 hours)

A. baumannii

313.5 (3-5 hours)

-1833 (3-5 hours)

-151.9 (3-5 hours)

P. aeruginosa

238.3 (3-5 hours)

10440 (3-5 hours)

702.4 (3-5 hours)

E. aerogenes

232.7 (3-5 hours)

-1979 (3-5 hours)

628.9 (3-5 hours)

Table 14: Generation Time of ESKAPE after EGCG-S treatment
The Effect of EGCG-S on Biofilm formation: Crystal Violet Assay and Resazurin
Assay
Biofilm formation was analyzed utilizing two methods: Crystal Violet and
Resazurin assay. The results are shown in Figures 11 and 13. E. faecalis showed a
significant reduction in biofilm formation utilizing Resazurin Fluorescence shown clearly
in Figures 13 and 14. Results were inconsistent, therefore, further studies are needed to
optimize the methodology.
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Absorbance (595nm)

Effect of EGCG-S on biofilm formation: Crystal
Violet Assay
4
3.5
3
2.5
2
1.5
1
0.5
0
Efm

Ef

Sa

Control

Kp

250 ug/mL

Ab

Pa

Ea

500 ug/mL

Figure 11: The effects of EGCG-S on biofilm formation utilizing the Crystal Violet
Assay on E. faecium (Efm), E. faecalis (Ef), S. aureus (Sa), K. pneumoniae (Kp), A.
baumannii (Ab), P. aeruginosa (Pa) and E. aerogenes (Ea). Two concentrations were
tested (250 µg/mL and 500 µg/mL).

% Inhibition

% Inhibition- Crystal Violet
Assay
200
150
100
50
0
-50
-100

151

89.8274925
8
40.95

Efm
-60

0.076

49.50
3.70

Ef
Sa
-29.05 -…

Kp -3.57
Ab
-47.60

250 ug/mL

500 ug/mL

14.31

Pa
Ea
-12.51
-33.11

Figure 12: EGCG-S percent inhibition of biofilm formation – Crystal Violet Assay
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Relative Light Units (RLU)

Effect of EGCG-S on biofilm formation
utilzing Rezazurin Flourescence Assay
30000
20000
Control

10000

250 ug/mL average
500 ug/mL average

0
Efm

Ef

Sa

-10000

Kp

Ab

Pa

Ea

Treatments

Figure 13: The effects of EGCG-S on biofilm formation utilizing the resazurin assay
on E. faecium (Efm), E. faecalis (Ef), S. aureus (Sa), K. pneumoniae (Kp), A. baumannii
(Ab), P. aeruginosa (Pa) and E. aerogenes (Ea). Two concentrations were tested (250
µg/mL and 500 µg/mL).
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60.00

50.45
50.28
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50.00
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40.00
30.00
20.00
10.00
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10.14

26.15
21.95
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5.65
2.24

1.03

0.00
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Sa

250 ug/mL
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500 ug/mL

Figure 14: EGCG-S percent inhibition of biofilm formation – Resazurin Assay
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Rapid Agar Plate Assay (RAPA): Colony Forming Units (CFU) Assay:
EGCG-S was effective in inhibiting growth in both pre and post application on the
bacteria as shown in Figure 15. Pre application percent inhibition ranged from 9.64%61.71%. Post application was more effective in most cases as seen in Figure 15.

Figure 15: Percent inhibition of CFU of E. faecium, E. faecalis, S. aureus and K.
pneumoniae pre and post application of EGCG-S.
Effect of EGCG-S on Microorganisms (Live vs. Dead Assay):
bacterial samples treated with EGCG-S were viewed in comparison to controls
utilizing the fluorescence scope. Figures 17a -17g, are the control bacteria under
fluorescence which are fluorescing green, indicating that the cells are alive. Figures 18a18g are the treated bacteria under fluorescence which are mostly red, indicating that they
are dead. The treated bacterial cells fluoresced red indicating that the treatment was
effective, in comparison to the cells that fluoresced green from that were alive in the control
(untreated).
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17a. E. faecium: Untreated

17b. E. faecium: Treated

16b. E. faecalis: Untreated

17b. E. faecalis: Treated

16c. S. aureus : Untreated

17c. S. aureus : Treated
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16d. K. pneumoniae: Untreated

17d. K. pneumoniae: Treated

16e.A.baumannii: Untreated

17e. A.baumannii: Treated

16f. P. aeruginosa: Untreated

17f. P. aeruginosa: Treated

16g: E. aerogenes: Untreated

17g: E. aerogenes: Treated
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Figure 16a -16g: RAPA post- application control bacteria under fluorescence, which are
fluorescing green indicating that the cells are alive. Figure 17a- 17g: RAPA post
application treated bacteria under fluorescence.
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Conclusion
All of the ESKAPE organisms utilized in this study were determined to be pure
via cytological and molecular techniques. EGCG-S was shown to enhance the
antimicrobial activity of various antibiotics, converting bacteria from resistant to
intermediate or resistant to sensitive. The most effective outcome was converting E.
faecalis from resistant to sensitive to Polymyxin B with a 150 % ZOI increase. The
following table is a summary of the Disk Diffusion results and the potential synergy
found in this study. Table 15 summarizes the antibiotics that worked the best in synergy
with EGCG-S in increasing the diameter (mm) of the zone of inhibition.

Organism
E. faecalis:
E . faecium
S. aureus
K. pneumoniae
A. baumannii
P. aeruginosa
E. aerogenes

Treatment (Antibiotics vs.
EGCG-S in conjunction with
antibiotics)
Erythromycin: Ià R
Polymyxin B: Rà S
Erythromycin: Ià R
Polymyxin B: Rà I
Erythromycin: Ià R
Polymyxin B: Ià R
Bacitracin Rà I
Erythromycin: Rà I
Vancomycin: Rà S
Bacitracin I à S
Polymyxin B I à S
Vancomycin Rà I
Chloramphenicol I à S
Polymyxin B I à S
Polymyxin B I à S
Bacitracin Rà I

Table 15: Summary of the most promising synergistic effect by organisms found in the
study.
The results indicated that EGCG-S potentially inhibited growth at both 250 and
500 µg/ml when testing the effects of EGCG-S on the growth of bacteria, however, 250
µg/ml was more effective in inhibiting bacterial growth and proliferation. The results of
the effects of EGCG-S on biofilm formation were inconsistent, therefore future studies to
optimize our methodology is required. Additionally, EGCG-S was able to kill the
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ESKAPE bacteria after post application treatment as seen in the Live vs. Dead Assay.
All in all, the burden of the antibiotic resistance ESKAPE pathogens continue to
increase. Therefore, there is a demand for new antimicrobial medications and natural
remedies that can potentially circumvent the threat MDR organisms present to our global
health(Antibiotic 2017; Shin et al. 2018). Previous treatment plans that were considered
the gold standard of care are no longer effective due to resistance. However, natural
remedies and techniques to treat infections are promising, as shown in this study utilizing
EGCG-S and in aforementioned studies. With research advancements, the development
of new natural preservatives, replacing antibiotics in our food and cattle, and using
polyphenols and plant extracts to treat MDR organisms we can potentially combat
antibiotic resistance.
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Future Studies
•
•
•
•

Monitor combination treatment (antibiotics & EGCG-S) on growth, viability and
biofilm formation.
Utilize the cell sorter to evaluate the population dynamics of bacteria in different
treatment conditions.
Conduct a molecular study of mechanisms of antibiotics & EGCG-S synergy.
Utilize primers discussed above to test our isolates for specific antibiotic
resistance genes to better understand their response to antibiotics and if EGCG-S
is able to disrupt encoded resistance.
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